Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H33ClN2.2ClH |
Molecular Weight | 505.95 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C=C1
InChI
InChIKey=SDBHDSZKNVDKNU-UHFFFAOYSA-N
InChI=1S/C28H33ClN2.2ClH/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24;;/h4-16,27H,17-21H2,1-3H3;2*1H
Molecular Formula | C28H33ClN2 |
Molecular Weight | 433.028 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22469258 | http://edudrugs.com/B/Bucladin-S.html
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22469258 | http://edudrugs.com/B/Bucladin-S.html
Buclizine, a piperazine derivative, is a sedating antihistamine with antimuscarinic and moderate sedative action. The drug is used mainly for its antiemetic action, particularly in the prevention of motion sickness, and in the treatment of migraine in combination with analgesics. The following side/adverse effects have been selected on the basis of their potential clinical significance: drowsiness; Incidence less frequent; blurred vision; dryness of mouth, nose, and throat; headache; nervousness, restlessness, or trouble in sleeping; upset stomach. The following drug interactions have been selected on the basis of their potential clinical significance: alcohol; anticholinergics or other medications with anticholinergic activity; apomorphine.
CNS Activity
Sources: http://www.pharmacorama.com/en/Sections/Histamin_3.php | https://www.ncbi.nlm.nih.gov/pubmed/20515533
Curator's Comment: Buclizine is the drug of the first antihistamine generation.Firstgeneration histamine H1-receptor antagonists readily penetrate the blood brain barrier and produce histamine blockade at histamine H1-receptors in the central nervous system.
Originator
Sources: https://www.google.com/patents/US2709169
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/22469258
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | BUCLADIN-S Approved UseFor prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems). |
|||
Sources: http://edudrugs.com/B/Bucladin-S/more.html |
Preventing | BUCLADIN-S Approved UseFor prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems). |
||
Palliative | Migraleve pink Approved UseTreating nausea and headache associated with migraine attacks that are not relieved by paracetamol, ibuprofen or aspirin alone. Launch Date2015 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.45 μg/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUCLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.22 μg × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUCLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.3 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUCLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Quantitation of buclizine hydrochloride in pharmaceutical formulations and human serum by RP-HPLC. | 2006 Oct |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC. | 2010 May-Jun |
Patents
Sample Use Guides
50 mg thirty minutes before travel. Dose may be repeated every four to six hours as needed. Usual adult prescribing limits - up to 150 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26921194
Treatment of MCF-7 cells with different concentrations for 72 h showed that buclizine (IC50: 19.18 ± 5.32 μM) revealed considerable growth inhibition.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:17:00 GMT 2023
by
admin
on
Fri Dec 15 16:17:00 GMT 2023
|
Record UNII |
58FQD093NU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5045091
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
7139-55-1
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
129-74-8
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
25141
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
DBSALT000197
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
m2744
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
65463
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
SUB00889MIG
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
100000091920
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
58FQD093NU
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
Bucladin
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201271
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
204-962-4
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
C65274
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
61193
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | |||
|
91070
Created by
admin on Fri Dec 15 16:17:00 GMT 2023 , Edited by admin on Fri Dec 15 16:17:00 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |